“…Interactions of some 5-HT 3 receptor antagonists with human cardiac ion channels are known and have been reported [15], and recently, the effect of palonosetron on QTc prolongation has been studied in an European doubleblind, randomized, placebo-controlled trial, which showed no significant effect on any ECG interval, including QTc duration, with intravenous palonosetron administered up to 2.25 mg, three times the study dose [16]. In the doubleblind, randomized phase III study, the incidences of QTc prolongation in the palonosetron group and in the granisetron group were comparable [8].…”